All relevant data are within the paper.

Introduction {#sec004}
============

Pathogen inactivation systems are proactive alternatives to conventional bacterial screening and prevention methods for blood transfusion products \[[@pone.0220163.ref001]\]. Several systems are currently available on the market such as the INTERCEPT^™^ Blood System, Mirasol^™^ and THERAFLEX^™^ \[[@pone.0220163.ref002]\]. The INTERCEPT^™^ Blood System for pathogen inactivation of platelets gained the CE mark in 2002 \[[@pone.0220163.ref003]\] and is routinely used in several European countries \[[@pone.0220163.ref004]\]. The system effectively reduces the accumulation of pathogens by blocking their ability to replicate \[[@pone.0220163.ref003]\]. The active compound used in the INTERCEPT System, amotosalen S-59, passes through cell membranes, bacterial walls, and viral envelopes and intercalates between helical regions of DNA and RNA \[[@pone.0220163.ref005]\]. Covalent crosslinks are formed between amotosalen S-59 and pyrimidine bases upon exposure to ultraviolet A (UVA) illumination, leaving most pathogenic organisms unable to replicate \[[@pone.0220163.ref003]\]. While successful inactivation is observed in general, non-enveloped viruses such as hepatitis A and hepatitis E show resistance to the treatment \[[@pone.0220163.ref003]\].

Implementing a pathogen inactivation system improves the safety of transfusion units and allows platelets to be stored for an extended period of up to seven days \[[@pone.0220163.ref003]\]. Blood banks must stock surplus transfusion units; with approximately 2 million reported annual platelet transfusions in the United States alone \[[@pone.0220163.ref006]\], this inevitably results in large quantities of expired platelets \[[@pone.0220163.ref007]\]. Although expired platelet concentrates are unfit for transfusion medicine due to safety concerns, their abundance of growth factors makes them suitable for use in cell cultures \[[@pone.0220163.ref008]\].

Human mesenchymal stromal cells (MSCs) are multipotent cells capable of undergoing *in vivo* differentiation into end-stage cell types of connective tissues \[[@pone.0220163.ref009]\]. They were initially described, in the 1960s, as plastic-adherent and fibroblast-like cells with clonogenic potential *in vitro* \[[@pone.0220163.ref010]\]. Today, they are recognized as a part of stem cell niches in the bone marrow \[[@pone.0220163.ref011]\] and are known to play a role in immunomodulation \[[@pone.0220163.ref012]\], as demonstrated by the prominent contribution of the cells in reversing graft-versus-host-disease \[[@pone.0220163.ref013]\]. Scientific interest in MSCs has developed in recent years, making them one of the most-studied human cell types related to cell-based therapy \[[@pone.0220163.ref014]\].

An *in vitro* expansion step is usually necessary to attain clinically relevant numbers of MSCs \[[@pone.0220163.ref015]\]. Successful expansion of MSCs requires that basal cell culture medium be supplemented with a source of mitogens, such as growth factors. To date, this has mostly been performed using fetal bovine serum (FBS), which contains low amounts of immunoglobins and complement factors \[[@pone.0220163.ref016]\]. However, concerns regarding the content of animal components and large lot-to-lot variability has initiated a quest for replacements \[[@pone.0220163.ref016]--[@pone.0220163.ref018]\]. Platelet derivatives such as human platelet lysates (hPL) are currently considered promising replacements for FBS \[[@pone.0220163.ref008],[@pone.0220163.ref019]--[@pone.0220163.ref022]\] due to their non-xenogeneic nature and abundance of growth factors \[[@pone.0220163.ref023]\]. hPL has successfully been produced from fresh platelets \[[@pone.0220163.ref024]\], expired platelets \[[@pone.0220163.ref008]\], and, most recently, from expired and pathogen inactivated platelets \[[@pone.0220163.ref022]\]; all have been found to either be comparable to or to outperform FBS.

hPL is commonly manufactured by exposing platelet concentrates to repetitive cycles of freezing and thawing, resulting in degranulation \[[@pone.0220163.ref021]\], but it can also be produced by CaCl~2~ activation \[[@pone.0220163.ref025]\], sonication \[[@pone.0220163.ref026]\], or by using a solvent/detergent strategy \[[@pone.0220163.ref027]\]. Degranulation causes the α-granules to release growth factors and cytokines into solution \[[@pone.0220163.ref028]\]. To obtain a sufficient volume of hPL, allogeneic hPL are typically pooled using up to 120 donors \[[@pone.0220163.ref029]\]; however, recent research has demonstrated that pooling can be done effectively using up to 250 donors \[[@pone.0220163.ref030]\]. The end product is refined by centrifugation and sterile filtration to remove platelet fragments \[[@pone.0220163.ref029]\].

Recently, emphasis has been placed on improving standardization in global good manufacturing practice (GMP)-grade hPL production, as current production methods vary between manufacturers \[[@pone.0220163.ref031]\]. Although pathogen inactivation techniques have recently been introduced into the preparation of transfusion products, they are predominantly applied in Europe, while blood banks in the United States and Asia primarily rely on bacterial screening systems such as BacT/ALERT to ensure product safety \[[@pone.0220163.ref032]\]. As a result, most platelets used for hPL production are currently not pathogen inactivated.

In this proof-of-concept study, hPL from pathogen inactivated platelet lysates (hPL-PIPL), where pathogen inactivation was applied after lysis of expired platelets, was compared to hPL produced from expired conventionally pathogen inactivated platelet concentrates (hPL-PIPC), where pathogen inactivation was applied after production of platelet concentrates. We evaluated and compared the total protein content and concentrations of selected soluble growth factors and cytokines between hPL-PIPL and hPL-PIPC. Furthermore, we compared long-term proliferation and tri-lineage differentiation of bone marrow-derived MSCs using hPL-PIPL and hPL-PIPC as cell culture media supplements in order to determine the feasibility of producing an effective cell culture supplement from hPL when pathogen inactivation is applied after platelet lysis.

Results {#sec005}
=======

Growth factor and cytokine concentrations are lower in hPL-PIPL than in hPL-PIPC {#sec006}
--------------------------------------------------------------------------------

Quantification of 37 soluble growth factors and cytokines was performed using Luminex xMAP technology following platelet lysate production. Each of the measured growth factors and cytokines was present at lower concentrations in hPL-PIPL than in hPL-PIPC ([Table 1](#pone.0220163.t001){ref-type="table"}). The mean decreases for all evaluated growth factors and cytokines in hPL-PIPL (as compared to hPL-PIPC) for two produced batches were 29 ± 15% (p \< 0.001) and 36 ± 19% (p \< 0.001). The mean differences between hPL-PIPL and hPL-PIPC in key growth factors for the two batches ranged from 4.2 to 36%: platelet-derived growth factor-AB/BB (PDGF-AB/BB) (4.2 ± 1.8%); platelet-derived growth factor-AA (PDGF-AA) (12 ± 17%), epidermal growth factor (EGF) (23.9 ± 7.8%); vascular endothelial growth factor (VEGF) (26.6 ± 0.62%); and basic fibroblast growth factor (FGF-2) (36.3 ± 1.8%).

10.1371/journal.pone.0220163.t001

###### Growth factor and cytokine concentrations in two batches of undiluted hPL.

![](pone.0220163.t001){#pone.0220163.t001g}

  Growth Factor / Cytokine                        Batch 23   Batch 24   Batch 23 vs. Batch 24                              
  ----------------------------------------------- ---------- ---------- ----------------------- ------- ------- ---------- ------------
  EGF                                             1992       1361       32                      346     291     16         22.9 ± 7.8
  Eotaxin                                         96         53         45                      129     88      32         38.2 ± 6.7
  FGF-2                                           517        320        38                      478     313     34         36.3 ± 1.8
  Fractalkine                                     234        196        16                      164     105     36         26 ± 10
  G-CSF                                           49         27         44                      57      27      53         48.5 ± 4.1
  GM-CSF                                          27         20         26                      27      14      48         37 ± 11
  IFNα2                                           76         49         35                      84      44      47         41.2 ± 6.2
  IFNγ                                            14         12         19                      14      8.5     40         29 ± 11
  IL-1α                                           59         50         16                      29      19      35         25.4 ± 9.6
  IL-1β                                           5.5        3.4        38                      6.4     2.6     59         48 ± 11
  IL-1RA                                          503        452        10                      1030    884     14         12.2 ± 2.0
  IL-2                                            7.8        6.1        23                      4.0     1.8     55         39 ± 16
  IL-3                                            6.3        4.3        32                      6.2     3.1     49         40.6 ± 8.4
  IL-4                                            31         17         47                      48      27      44         45.5 ± 1.1
  IL-5                                            34         28         16                      82      69      16         15.7 ± 0.0
  IL-6                                            13         7.9        40                      12      3.3     72         56 ± 16
  IL-7                                            30         20         32                      36      22      40         36.4 ± 3.9
  IL-8                                            50         38         24                      76      64      16         19.9 ± 3.8
  IL-9                                            10         7.2        29                      6.5     3.9     39         34.3 ± 5.0
  IL-10                                           20         14         30                      7       2.4     65         48 ± 18
  IL-12p40                                        61         51         16                      62      32      49         33 ± 16
  IL-12p70                                        11         6.2        44                      12      6.2     47         45.5 ± 1.5
  IL-13                                           183        176        3.7                     433     372     14         8.8 ± 5.2
  IL-15                                           12         6.6        45                      8.6     3.6     59         51.6 ± 7.1
  IL-17A                                          14         14         4.1                     10      5.5     43         23 ± 19
  IP-10                                           120        58         52                      101     51      49         50.7 ± 1.4
  MCP-1                                           157        111        30                      185     157     15         22.4 ± 7.4
  MCP-3                                           301        276        8.3                     520     491     5.7        7.0 ± 1.3
  MDC                                             705        192        73                      754     230     69         71.1 ± 1.7
  MIP-1α                                          24         22         11                      33      30      8.8        9.8 ± 1.0
  MIP-1β                                          123        82         34                      165     127     23         28.4 ± 5.4
  PDGF-AA                                         15850      11232      29                      9105    9548    -4.9       12 ± 17
  PDGF-AB/BB                                      27802      27146      2.4                     25157   23661   5.9        4.2 ± 1.8
  TGF-α                                           3.0        1.8        40                      4.1     1.9     53         46.5 ± 6.5
  TNFα                                            24         16         35                      26      15      42         38.5 ± 3.5
  TNFβ                                            266        236        11                      570     490     14         12.7 ± 1.4
  VEGF                                            538        392        27                      441     327     26         26.6 ± 0.6
  Mean ± SD (%)                                                         29 ± 15                                 36 ± 19    32 ± 16
  p-value[^c^](#t001fn003){ref-type="table-fn"}                         \< 0.001                                \< 0.001   \< 0.001

^*a*^ Difference (%) between hPL-PIPC and hPL-PIPL within individual batches (Batch 23 and Batch 24). Note that the concentrations for all growth factors and cytokines were lower in hPL-PIPL.

^*b*^ Mean ± SD (%) represents the mean difference between hPL-PIPC and hPL-PIPL for both batches (n = 4).

^*c*^ p-values are reported on the overall differences between treatments (hPL-PIPC and hPL-PIPL) in individual batches (23 and 24) and for both batches combined. p-values were determined using a paired ratio t-test.

Proliferation of MSCs in hPL-PIPL is comparable to, but slower than, that in hPL-PIPC {#sec007}
-------------------------------------------------------------------------------------

Proliferation of MSCs originating from the bone marrow of two individual donors were assessed during nine cell passages ([Fig 1](#pone.0220163.g001){ref-type="fig"}). Cumulative population doublings (CPDs) were assessed from passage 4 through passage 9. MSCs grown in cell culture media supplemented with hPL-PIPL (hPL-PIPL-MSCs) proliferated significantly slower than hPL-PIPC-MSCs (p \< 0.001) from passage 5 through passage 9. At the end of passage 9, MSCs from Donor 6 had reached 19.42 ± 0.10 CPDs and 21.25 ± 0.03 CPDs with hPL-PIPL and hPL-PIPC supplementation, respectively, and MSCs from Donor 13 had reached 10.50 ± 0.40 CPDs and 12.80 ± 0.20 CPDs.

![Long-term proliferation of MSCs, expressed as cumulative population doublings.\
Proliferation of MSCs from two donors (D6 and D13) was evaluated in cell culture media supplemented with hPL-PIPC or hPL-PIPL after passage 3 (indicated by the vertical dotted line). Points represent mean ± SEM at the end of each passage (n = 6 cell cultures per passage, assessed in two independent experiments). Asterisks (\* p \< 0.05) indicate statistical significance between hPL-PIPC and hPL-PIPL for an individual donor, evaluated via a two-way ANOVA with Tukey's post hoc test.](pone.0220163.g001){#pone.0220163.g001}

Tri-lineage differentiation is not affected by the timing of pathogen inactivation {#sec008}
----------------------------------------------------------------------------------

hPL-PIPL-MSCs were successfully differentiated into osteogenic, adipogenic and chondrogenic lineages. Osteogenic differentiation was evaluated during 28 days of stimulation in osteogenic media. Alkaline phosphatase (ALP) activities in both hPL-PIPL-MSCs and hPL-PIPC-MSCs were significantly elevated after seven days as compared to unstimulated control cultures (p \< 0.05) ([Fig 2](#pone.0220163.g002){ref-type="fig"}). A peak in ALP activity was observed at day 14 for both hPL-PIPL-MSCs (3.6 ± 0.1 nmol (p-nitrophenol)/min) and hPL-PIPC-MSCs (3.8 ± 0.1 nmol (p-nitrophenol)/min), followed by fairly consistent ALP activity between days 14 and 28. Comparable mineralization between hPL-PIPC and hPL-PIPL MSCs was demonstrated by Alizarin Red S staining after 28 days of differentiation ([Fig 3A and 3B](#pone.0220163.g003){ref-type="fig"}).

![Alkaline phosphatase activity during osteogenic differentiation.\
MSCs were differentiated in osteogenic media supplemented with hPL-PIPL or hPL-PIPC, with MSCs grown in expansion media included as a control. Points represent means ± SEM (n = 6 cell cultures per timepoint, assessed in two independent experiments). Asterisks (\* p \< 0.05) indicate statistical significance versus the control, evaluated via a two-way ANOVA with Tukey's post hoc test.](pone.0220163.g002){#pone.0220163.g002}

![Tri-lineage differentiation of MSCs.\
MSCs differentiated using hPL-PIPC are shown in A, C, and E, while MSCs differentiated using hPL-PIPL are shown in B, D, and F. A and B show Alizarin Red S staining, used to demonstrate mineralization (black arrows) after 28 days of stimulation in osteogenic medium. C and D show Oil Red O staining, used to demonstrate accumulation of lipid droplets (black arrows) after 14 days of stimulation in adipogenic medium. E and F show Masson's trichrome staining, used to demonstrate collagen fibers (black arrows) and lacunae formation (yellow arrows) after 35 days of chondrogenic stimulation.](pone.0220163.g003){#pone.0220163.g003}

Adipogenic differentiation was evaluated during 14 days of stimulation in adipogenic media. Accumulation of lipid droplets in the cell periphery was confirmed by positive Oil Red O staining after 7 days. After 14 days of differentiation, lipid droplets were distributed throughout the cells ([Fig 3C and 3D](#pone.0220163.g003){ref-type="fig"}).

Chondrogenic differentiation was evaluated during 35 days of stimulation in chondrogenic media. After 28 days of differentiation, the concentration of glycosaminoglycans (GAGs) was significantly higher (p \< 0.05) in cell pellets supplemented with both hPL-PIPC and hPL-PIPL than in unstimulated control cell pellets ([Fig 4](#pone.0220163.g004){ref-type="fig"}). GAG concentration remained significantly higher than the control during differentiation of hPL-PIPC-MSCs at day 35 (p \< 0.05), while GAG concentration decreased again in hPL-PIPL-MSCs by day 35 such that there was no longer a significant difference from the control. No statistically significant differences were observed between hPL-PIPC-MSCs and hPL-PIPL-MSCs. Lacunae formation and accumulation of collagen fibers were demonstrated after 35 days of differentiation using Masson's trichrome staining ([Fig 3E and 3F](#pone.0220163.g003){ref-type="fig"}).

![Concentration of glycosaminoglycans.\
GAG concentration was measured in MSC pellets stimulated with chondrogenic media supplemented with either hPL-PIPC or hPL-PIPL. Pellets grown in expansion media were included as a control. Points represent mean ± SEM (n = 2 pellets per timepoint, assessed in two individual experiments). Asterisks (\* p \< 0.05) indicate statistical significance versus the control, evaluated via a two-way ANOVA with Tukey's post hoc test.](pone.0220163.g004){#pone.0220163.g004}

Discussion {#sec009}
==========

In this proof-of-concept study, the feasibility of producing cell culture supplements from hPL derived from pathogen inactivated platelet lysates (hPL-PIPL) was evaluated via a comparison with a supplement created from conventional hPL derived from pathogen inactivated platelet concentrates (hPL-PIPC). We evaluated the composition of the lysates as well as their applicability for use as supplements to support BM-MSC proliferation and tri-lineage differentiation. As it has previously been shown that hPL performance as a cell culture supplement is comparable to or better than that of FBS \[[@pone.0220163.ref008]. [@pone.0220163.ref022], [@pone.0220163.ref024]\], FBS was not included in this proof-of-concept work.

Concentrations of all 37 selected soluble growth factors and cytokines were significantly reduced in hPL-PIPL compared to hPL-PIPC, with an average difference of 32 ± 16% (p \< 0.001). Of the key growth factors, we found that the differences between hPL-PIPC and hPL-PIPL in PDGF-AB/BB and PDGF-AA were relatively small, at 4.2 ± 1.8% and 12 ± 17%, respectively. The effects on EGF, VEGF, and FGF-2 were slightly higher, with observed reductions in hPL-PIPL of 23.9 ± 7.8%, 26.57 ± 0.62, and 36.3 ± 1.8%, respectively. As several growth factors within the α-granules of the platelets are important for MSC proliferation and differentiation \[[@pone.0220163.ref033],[@pone.0220163.ref034]\], the composition following production and storage is an important marker for platelet lysate quality. The effects of pathogen inactivation on growth factor stability during storage have previously been studied. It was demonstrated that UVC treatment of platelet concentrates had no effect on concentrations of EGF, FGF-2, PDGF-AB, VEGF, or insulin-like growth factor (IGF) \[[@pone.0220163.ref035]\]. In a study specifically conducted on the INTERCEPT^™^ Blood System for pathogen inactivation, it was found that amotosalen plus UVA treatment mainly targets proteins of intracellular platelet activation pathways \[[@pone.0220163.ref036]\]. In addition, UV illumination of platelets combined with riboflavin or amotosalen seems to trigger activation of p38 mitogen-activated protein kinases (p38MAPK), leading to platelet degranulation \[[@pone.0220163.ref037]\]. However, to our knowledge this is the first study evaluating the effect of pathogen inactivation on lysed platelets compared to intact platelet concentrates. It can be speculated that, as a result of platelet cargo being released into solution of hPL-PIPL at the time of pathogen inactivation, the difference in composition between hPL-PIPC and hPL-PIPL is caused by UVA photodegradation, since light exposure can lead to irreversible changes in the primary, secondary, and tertiary structure of proteins \[[@pone.0220163.ref038]\]. It should be noted that the individual differences in soluble growth factors and cytokines between the two batches produced in this study limits the ability to generalize the results of changes to growth factors and cytokines beyond this proof-of-concept study.

As it has been suggested that hPL should contain high concentrations of PDGF-AB, VEGF, EGF, FGF-2, and transforming growth factor beta 1 (TGF-β1), and low concentrations of IGF-1, we examined the long-term proliferation of MSCs from two donors in terms of cumulative population doublings (CPDs). Total CPDs were higher for both of the donor hPL-PIPC-MSCs than for the hPL-PIPL-MSCs, indicating higher mitogenic effects in conventional hPL-PIPC. It is evident that EGF and VEGF activate the Raf-MEK-ERK pathway by binding to transmembrane receptor proteins at the plasma membrane \[[@pone.0220163.ref039]\]. Less activation of the Raf-MEK-ERK pathway may contribute to less cell proliferation and failure to prevent apoptosis. However, it is important to mention that high CPDs should not be viewed as a success criterion in isolation; successful expansion of MSCs must also include retention of genomic stability and avoidance of tumorigenicity \[[@pone.0220163.ref040]\]. These parameters were not within the scope of this study, but to fully elucidate the ability of hPL-PIPL to support long-term proliferation and clinical potential of MSCs *in vitro*, genomic stability and tumorigenicity is important. Future work should consider these factors.

Tri-lineage differentiation potential was examined *in vitro* by stimulating MSCs in osteogenic, adipogenic, and chondrogenic media. After 14 days of differentiation, both hPL-PIPC-MSCs and hPL-PIPL-MSCs differentiating into osteoblasts demonstrated significantly higher ALP activity compared to unstimulated control cultures. The presence of peak ALP levels around day 14 is a marker for osteogenic differentiation \[[@pone.0220163.ref041]\] and, in our study, indicated osteogenic differentiation potential. This was supported by mineralization and bone-like nodule formation after 28 days of differentiation in both treatments.

Adipogenic differentiation potential was evaluated over the course of 14 days. As mature adipocytes predominantly consist of lipid droplets \[[@pone.0220163.ref042]\], we used positive Oil Red O staining to visualize the transition from MSCs into adipocytes. Morphological alterations from spindle-shaped MSCs toward round adipocytes were observed after 7 days in both hPL types. Similarly, lipid droplets had formed at the periphery of the cells by day 7, and after 14 days the lipid droplets took up most of the intracellular space.

Finally, we evaluated chondrogenic differentiation potential over a period of 35 days. Cell pellets from both hPL-PIPC-MSCs and hPL-PIPL-MSCs had accumulated significantly more glycosaminoglycans (GAGs) after 28 days of differentiation than unstimulated control cultures. This was consistent at day 35 for hPL-PIPC-MSCs, whereas the GAG concentration decreased between days 28 and 35 for hPL-PIPL-MSCs. To evaluate changes within pellet structures, the pellets were sectioned and stained with Masson's trichrome. During differentiation, we observed lacunae formation and collagen fiber formation, which confirmed successful chondrogenic differentiation.

Based on the preliminary results obtained from this study, it appears that the application of pathogen inactivation techniques after platelet expiry and lysate production is possible and may prove to be a valuable tool in the pursuit of optimal safety and standardization in therapeutic-grade human platelet lysate production. Despite decreased growth factors and cytokines in hPL-PIPL compared to hPL-PIPC, levels were shown to be sufficient in hPL-PIPL to support MSC proliferation and differentiation into osteoblasts, adipocytes, and chondrocytes.

The results of this work imply that further research into the suitability of applying pathogen inactivation to lysates from expired platelets is warranted. Given that this was a proof-of-concept study, several limitations should be addressed in further research. Firstly, a larger number of hPL batches should be evaluated in order to better evaluate the changes in growth factors and cytokines based on the hPL production method, as there were large differences between the two batches used in this study. A comparison to an FBS control would also be warranted, in order to compare the levels of growth factors and cytokines in hPL-PIPL supplements to those found in FBS supplements. In addition, it would be valuable to examine the effect of hPL production method on genomic stability and tumerogenicity.

Conclusion {#sec010}
==========

In this proof-of-concept study, we demonstrated that functional hPL cell culture supplements can be produced by performing pathogen inactivation after platelet lysis of expired and previously untreated platelet concentrates (hPL-PIPL). hPL-PIPL supported long-term cell proliferation and tri-lineage differentiation of BM-MSCs. While hPL-PIPL performed comparably to hPL-PIPC in terms of tri-lineage differentiation, lower cumulative population doublings (CPDs) were observed for hPL-PIPL. hPL-PIPL was also found to contain lower concentrations of key growth factors, suggesting that the timing of pathogen inactivation may affect the mitogenic potential of hPL rather than differentiation potential. Further work is necessary to evaluate the practical implications of the differences between hPL-PIPL, hPL-PIPC, and FBS on the effectiveness of hPL-PIPL as a cell culture supplement.

Materials and methods {#sec011}
=====================

Preparation of platelet lysates {#sec012}
-------------------------------

Study was approved by National Bioethics committee number VSN19-189. Four platelet concentrates (PCs) were prepared from a total of 32 buffy coats according to standard procedure at the Blood Bank, Landspitali (The National University Hospital of Iceland), Reykjavík, Iceland, as specified in [Table 2](#pone.0220163.t002){ref-type="table"}. Two separate batches of PCs (batch nos. 23 and 24) were each prepared by pooling two buffy coat-derived PCs together. Each pooled batch represented 16 whole blood donations obtained from healthy donors of the Blood Bank. Each batch was further split into two units and exposed to pathogen inactivation at different timepoints. The first unit, hPL-PIPC, was exposed to pathogen inactivation less than 24 hours post donation using the INTERCEPT^™^ Blood System (Cerus Corporation, Concord, CA, USA), which involves exposure to amotosalen S-59 and UVA illumination, according to manufacturer's protocol. Following pathogen inactivation, the PCs were placed into a platelet agitator at 22 ± 2°C for seven days until expiration, and then stored at -80°C for three weeks prior to platelet lysate production. The second unit, hPL-PIPL, was placed directly into the platelet agitator at 22 ± 2°C without being pathogen inactivated, stored for seven days until expiration, and then transferred to -80°C storage for three weeks. Pathogen inactivation for this second unit was performed after platelet lysis.

10.1371/journal.pone.0220163.t002

###### Platelet concentrate characteristics.

![](pone.0220163.t002){#pone.0220163.t002g}

  PC No.   Number of buffy coats[^a^](#t002fn001){ref-type="table-fn"}   Mean platelet count (× 10^9^)   Batch no.                
  -------- ------------------------------------------------------------- ------------------------------- ----------- ------------ ----
  1        8                                                             7                               1           278 ± 88.6   23
  2        8                                                             4                               4           211 ± 50.5   23
  3        8                                                             8                               0           197 ± 40.2   24
  4        8                                                             5                               3           195 ± 25.4   24
  Total    32                                                            24                              8           220 ± 34.1   

^*a*^ Four buffy coat-derived platelet concentrates (PC) from donors with either O RhD positive (O+) or O RhD negative (O-) blood groups comprised the starting material.

The expired PCs were collected and subjected to platelet lysis by three cycles of thawing at 37°C and freezing at -80°C to initiate degranulation. After the third cycle, the platelet lysates were aliquoted in 50-mL centrifugation tubes (Corning Science, Reynosa Tamaulipas, Mexico). Platelet fragments were removed by centrifugation at 4975 × g for 20 minutes using a Heraeus Multifuge X3 (Thermo Scientific, Waltham, Massachusetts, USA). This centrifugation step was repeated after the supernatants (platelet lysates) from each tube were transferred to new 50-mL centrifugation tubes. Prepared lysates from each unit were pooled. The hPL-PIPC units were distributed into 45 mL aliquots and stored at -20°C in a freezer (Gram BioLine, Vojens, Denmark). In addition, 1 mL and 5 mL aliquots were prepared for composition analysis and adipogenic differentiation, respectively, and stored at -20°C prior to analysis. The hPL-PIPL units were injected into sterile bags (Cerus Corporation, Concord, CA, USA) and exposed to pathogen inactivation with the INTERCEPT^™^ Blood System, according to the manufacturer's protocol, before being aliquoted and stored at -20°C as above.

These undiluted platelet lysates were used for experimentation within 18 months of storage.

Growth factor and cytokine quantification {#sec013}
-----------------------------------------

The undiluted platelet lysates were analyzed using Luminex xMAP Technology (EMD Millipore Corporation, Billerica, MA, USA) to quantify 37 soluble growth factors and cytokines. The Human Cytokine/Chemokine Magnetic Bead Panel (HCYTOMAG-60K, Millipore) was used; it applies microspheres and fluorescent signaling to quantify EGF, Eotaxin, FGF-2, Fractalkine, G-CSF, GM-CSF, IFNα2, IFNγ, IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12P40, IL-12P70, IL-13, IL-15, IL-17A, IL-1RA, IP-10, MCP-1, MCP-3, MDC, MIP-1α, MIP-1β, PDGF-AA, PDGF-AB/BB, TGF-α, TNFα, TNFβ, and VEGF. The concentrations in hPL-PIPL were compared to those in hPL-PIPC and expressed as percentage difference in relation to hPL-PIPC ([Eq 1](#pone.0220163.e001){ref-type="disp-formula"}, where \[GF/C\]~hPL‑PIPx~ refers to the concentration of a particular growth factor or cytokine in the hPL-PIPC or hPL-PIPL treatment).

![](pone.0220163.e001.jpg){#pone.0220163.e001g}
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Cell culturing {#sec014}
--------------

Mesenchymal stromal cells originating from the bone marrow of two healthy human donors were purchased from Lonza (Walkersville, MD, USA) and stored at -180°C in liquid nitrogen prior to experimentation. The cells tested negative for viral infections and mycoplasma. Prior to experimentation, the MSCs were cultured in a cell culture medium supplemented with hPL-PIPC through passage 3. Subsequently, the MSCs were distributed into two cell culture flasks supplemented with either hPL-PIPC or hPL-PIPL at the time of cell split (between passage 3 and passage 4). MSCs in passage 5 were used for experimentation.

The culture medium used was a complete cell culture medium (referred to as "expansion medium" in this study) consisting of Dulbecco's Modified Eagle Medium (DMEM) / F12 + Glutamax supplement (Gibco, Grand Island, NY, USA) with 1% penicillin/streptomycin (Gibco) and 2 IU/mL heparin (Leo Pharma A/S, Ballerup, Denmark), supplemented with a sufficient amount of either hPL-PIPC (to produce hPL-PIPC-MSCs) or hPL-PIPL (to produce hPL-PIPL-MSCs) to achieve a final concentration of 9%. Specifically, after allowing solutions to reach ambient temperature, 50 mL of platelet lysate was centrifuged at 4975 × g for 10 minutes and added to 500 mL DMEM / F12 + Glutamax along with 5 mL of penicillin/streptomycin and 200 μL heparin. The medium was allowed to sit for 10 minutes prior to sterile filtration. Sterile filtration was performed using a 0.45 μm low protein-binding funnel (Corning Incorporated, NY, USA) in a closed system. Finally, the medium was aliquoted into 45-mL centrifugation tubes (Corning Incorporated) and stored at -20°C until use. Once thawed for use in cell cultures, the medium was maintained at 4°C in a laboratory refrigerator (Angelantoni Life Sciences, Massa Martana, Italy) for a maximum of seven days.

Incubation was done in a Steri-Cult CO2 Incubator, HEPA Class 100 (Thermo Scientific) under the following conditions: 37°C; 5% CO~2~, and 95% humidity.

Cell expansion was performed in different vessels appropriately selected for each experiment at a seeding density of 6000 cells/cm^2^. For the initial cell expansion prior to experimentation, MSCs were expanded in 20 mL of expansion medium in Nunc^™^ EasYFlask^™^ 75 cm^2^ (T75) cell culture flasks (Thermo Fischer Scientific Nunc A/S, Roskilde, Denmark). For long-term proliferation studies, MSCs were expanded in 5 mL of expansion medium in Nunc^™^ EasYFlask^™^ 25 cm^2^ (T25) cell culture flasks (Thermo Fischer Scientific Nunc A/S). In both cases, the expansion medium was replaced every two to three days.

Cell passaging was performed upon reaching 80--90% confluency, as determined visually by daily inspection using a Leica DM IRB inverted contrast microscope (Leica Microsystems, Wetzlar, Germany). In brief, the MSCs were gently washed with 1X PBS (Gibco) and dissociated from the surface in 0.25% 1X Trypsin-EDTA (Gibco) for 5 minutes. Preheated expansion medium was added to neutralize the trypsin-EDTA before the cells were centrifuged at 609 × g for 5 minutes. After centrifugation, the supernatant was discarded and the pellet was carefully resuspended in 1 mL preheated medium prior to cell counting. The cells were diluted 5X by mixing 20 μL resuspended cells, 30 μL 1X PBS, and 50 μL 0.4% trypan blue stain (Gibco) in a 1.5-mL micro tube (SARSTEDT AG & Co., Nümbrecht, Germany). The cell solution was loaded onto a hemocytometer (BRAND GMBH + CO KG, Wertheim, Germany), covered by a glass, and counted at 50X magnification. Viable MSCs were identified by the retention of their round morphology and by their lack of trypan blue uptake. Viable MSCs located in the four corner squares were counted twice using the upper and lower chambers and averaged to estimate the number of cells. If the sum of the four corner squares in a single chamber exceeded 200 viable MSCs, the cell solution was diluted further and the cell count repeated. Cell passaging was completed by seeding 6000 cells/cm^2^ into a new cell culture vessel.

Long-term proliferation was evaluated by expanding and passaging MSCs in T25 cell culture flasks. Initially, MSCs entering passage 5 were seeded into six T25 cell culture flasks and expanded in cell culture media supplemented with either hPL-PIPC or hPL-PIPL. The expansion medium was replaced every two to three days, and cell passaging was carried out upon reaching 80--90% confluency. All cell culture flasks were passaged on the same day and the number of population doublings (PDs) was determined using [Eq 2](#pone.0220163.e002){ref-type="disp-formula"}, where N0 and N1 represent the number of cells seeded and cells harvested, respectively.
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Cumulative population doublings (CPDs) were expressed as the sum of the PDs obtained in each passage. Cell expansion was terminated upon achieving recovery rates of less than 100% of the seeded cell number after a maximum of 14 days in culture. Daily monitoring was performed to assess morphological alterations.

Tri-lineage differentiation {#sec015}
---------------------------

MSCs in passage 5 were used to evaluate *in vitro* tri-lineage differentiation potential. Osteogenic and adipogenic differentiation were performed simultaneously using the same cell cultures. Chondrogenic differentiation was performed separately due to the large number of required cells.

Osteogenic differentiation {#sec016}
--------------------------

Osteogenic differentiation was evaluated at various timepoints during 28 days of stimulation in osteogenic medium. The osteogenic medium consisted of 45 mL DMEM / F12 + Glutamax (Gibco) supplemented with 5 mL platelet lysate, 50 μL dexamethasone (Sigma-Aldrich, St. Louis, MO, USA), 50 μL human/murine/rat BMP-2 (Peprotech, Rocky Hill, NJ, USA), 50 μL L-ascorbic acid (Sigma-Aldrich), and 108 mg β-glycerophosphate disodium salt hydrate (Sigma-Aldrich). An increase in alkaline phosphatase activity and positive staining for mineralization were used as markers. In brief, 3500 cells/cm^2^ were seeded in quadruplicate in 6-well tissue culture plates (Corning Incorporated) and in triplicate in 12-well tissue culture plates (Corning Incorporated) for each timepoint. Control plates were included by seeding 5500 cells/cm^2^ in expansion media in absence of osteogenic stimulation. Plates were incubated at 37°C, 5% CO~2~, and 95% humidity for up to 28 days. The cell culture medium was replaced every two to three days. The left half of the 12-well plates was used to quantify ALP activity, while the right half was used to detect mineralization by staining with Alizarin Red S.

Enzymatic activity of ALP was evaluated after 7, 14, 21, and 28 days of osteogenic differentiation. Briefly, 0.02% Triton-X (Sigma-Aldrich) diluted in 1X PBS was added to all samples, and then the cells were scraped off the surface and transferred to a 1.5-mL micro tube. The cells were vortexed and then centrifuged at 13,200 × g for 15 minutes at 4°C. After centrifugation, the supernatant was transferred to a new micro tube and mixed with 500 μL of p-nitrophenyl phosphate (pNPP) solution, prepared using SIGMAFAST^™^ pNPP and SIGMAFAST^™^ Tris Buffer (Sigma-Aldrich). Next, the solution was incubated for 45 minutes at 37°C protected from light, and the absorbance was measured at 400 nm. Each sample reading was corrected by the average absorbance of three blank replicates. ALP activity (nmol (p-nitrophenol)/min) was calculated using [Eq 3](#pone.0220163.e003){ref-type="disp-formula"}, $$\mspace{720mu} activity\mspace{720mu} = \mspace{720mu}\frac{\frac{OD}{18.8}}{t}x\mspace{720mu} 1000\mspace{720mu},$$ where OD refers to the optical density obtained at 400 nm (-), 18.8 is the extinction coefficient of p-nitrophenol (μmol^-1^), t is time (min), and 1000 is used to convert μmol to nmol.

Alizarin Red S staining was performed to visualize mineralization during osteogenic differentiation. Cell cultures were collected and fixed in 4% paraformaldehyde after 7, 14, 21, and 28 days of osteogenic differentiation and stored at 4°C prior to staining. Cells were washed three times with distilled water (dH~2~O) before adding a 2% Alizarin Red solution containing Alizarin Red S dye (Sigma-Aldrich) diluted in dH~2~O. The cells were placed on a rotating shaker and stained for 20 minutes at room temperature, followed by four washing steps using dH~2~O. The dye was allowed to dry for 24 hours by inverting the plates on paper towels. The following day, images were captured using inverted contrast microscope imaging, and alterations in morphology and formation of bone-like nodules were evaluated.

Adipogenic differentiation {#sec017}
--------------------------

Adipogenic differentiation was evaluated after 7 and 14 days of stimulation in adipogenic medium. Adipogenic medium consisted of 22.5 mL StemPro^®^ Adipocyte Differentiation Basal Medium (Gibco), 2.5 mL StemPro^®^ Adipogenesis Supplement (Gibco), 0.25 mL penicillin/streptomycin, 2.5 mL platelet lysate, and 20 μL heparin.

In brief, 10,000 cells/cm^2^ were seeded in triplicate Nunc^™^ 9 cm^2^ Slideflasks (Thermo Fischer Scientific Nunc A/S). Control slideflasks were included by seeding 5500 cells/cm^2^ in expansion media in absence of adipogenic stimulation. Sideflasks were incubated at 37°C, 5% CO~2~, and 95% humidity for up to 14 days. The MSCs were allowed to reach a confluency of 50--70% in expansion media prior to introduction of the adipogenic medium. The cell culture medium was replaced every two to three days. Cultures in the 9 cm^2^ slideflasks were washed three times in 1X PBS and fixed in 3 mL of 4% paraformaldehyde and stored at 4 °C after 7 or 14 days prior to Oil Red O staining.

Upon termination of the experiment, the slideflasks were collected and sent to the Department of Pathology (Landspitali, Háskólasjúkrahús, Reykjavík, Iceland) where Oil Red O staining was performed according to departmental protocols. Positive Oil Red O-stained lipid droplets were used as markers of adipogenic differentiation.

Chondrogenic differentiation {#sec018}
----------------------------

Chondrogenic differentiation was evaluated after 14, 28, and 35 days of stimulation in chondrogenic medium. Chondrogenic medium consisted of 47.9 mL DMEM / F12 + Glutamax supplemented with 9% hPL, 1% penicillin/streptomycin, 50 μL L-ascorbic acid, 50 μL dexamethasone, 500 μL sodium pyruvate (Sigma-Aldrich), 500 μL L-proline (Sigma-Aldrich), 500 μL ITS+ (Gibco) and 5 μL of 10 ng/μL TGF-β3. Production of glycosaminoglycans, as well as positive collagen fibers and lacunae formation visualized by chondrocytic pellet staining with Masson's trichrome were used as markers of chondrogenic differentiation.

In brief, 250,000 cells were seeded in ten 1.5-mL micro tubes containing 0.5 mL chondrogenic media for each timepoint. Control micro tubes were included by seeding 250,000 cells in expansion media in absence of chondrogenic stimulation. Pellets were formed by centrifugation at 152 × g using a Sorvall Instruments RC5C centrifuge (Thermo Fischer Scientific). The caps were punctured with a sterile needle to allow air exchange, and the tubes were incubated at 37°C, 5% CO~2~, and 95% humidity for up to 35 days. After 18--24 hours, the tubes were gently agitated to detach the pellets from the wall of the micro tubes. To minimize the stress on the pellets, half of the cell culture medium was replaced every second day. At each sampling timepoint (14, 28, and 35 days), three pellets were analyzed for GAG content and two pellets were prepared for histological staining.

To prepare pellets for the GAG assay, the three pellets were pooled into a micro tube containing 500 μL papain extraction reagent (Sigma-Aldrich). The samples were then transferred to a Grant-Bio PHMT heating block (Grant Instruments Ltd, Shepreth, Cambridgeshire, UK) and fully digested at 65°C for a maximum of seven hours. After digestion, the samples were centrifuged at 9660 × g and the supernatants were transferred to new micro tubes and stored at -80°C.

To prepare pellets for histological staining, the pellets were collected and washed in 1X PBS prior to fixation in 0.5 mL 4% paraformaldehyde in new micro tubes. The samples were stored at 4°C prior to histological staining.

The Biocolor Blyscan Sulfated Glycosaminoglycan Assay B1000 (Biocolor Ltd, County Antrim, United Kingdom) was used to quantify the concentrations of GAGs. The assay was performed according to the manufacturer's protocol. In brief, standards diluted in papain extraction reagent were prepared containing GAGs in the working range of 0--5 μg/mL. 1 mL of Blyscan dye reagent was added to a new micro tube prepared for each standard and sample. 100 μL of each standard and sample was then added to the new micro tubes and mixed with the Blyscan dye reagent for 30 minutes on a mechanical shaker (Heidolph, Schwabach, Germany). After incubation, the micro tubes were centrifuged for 10 minutes at 9660 × g. The supernatant was separated from the pellet by inverting the micro tubes carefully before adding 0.5 mL dissociation reagent. Prior to quantification, the micro tubes were vortexed to release bound dye into the solution. 200 μL of each standard and sample was loaded into a 96-well tissue culture plate in triplicate and measured at 656 nm using a Multiskan^®^ spectrum spectrophotometer (Thermo Scientific, Vantaa, Finland). The average absorbance of the blank replicates was subtracted from each standard and sample. The GAG concentration of each sample was determined using the standard curve. To express GAG concentration per pellet, the values were divided by three to account for the number of pooled pellets.

Upon experimental termination, the micro tubes were collected and sent to the Department of Pathology (Landspitali, Háskólasjúkrahús, Reykjavík, Iceland). Masson's trichrome and hematoxylin and eosin staining were performed according to departmental protocols.

Statistical analysis {#sec019}
--------------------

Statistical comparisons were performed using GraphPad Prism Version 7.04 software (GraphPad Software, Inc., San Diego, CA, USA). Paired t-tests were performed to analyze differences in total protein. Ratio paired t-tests were performed to analyze differences in the content of growth factors and cytokines. Differences in proliferation and differentiation were analyzed using a two-way ANOVA followed by multiple comparisons using Tukey's post hoc test. Differences were considered significant at p \< 0.05.

The sample size (N) for each experiment refers to the number of experimental units derived from biological units using separate cell culture vessels. Nomenclature and principle were adapted from Lazic et al. \[[@pone.0220163.ref043]\].

We would like to thank Ragna Landrö for processing the platelet concentrates and Sigrún Bærings Kristjánsdóttir for support with staining procedures.
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1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Partly

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes
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\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?
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Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Christensen and colleagues report results of an ex-vivo study of bone-marrow derived MSCs expansion and differentiation with human platelet lysates (hPL) with two different pathogen inactivation processes. Specifically, this study addresses the issue that clinical application of MSCs usually required and in vitro expansion step for clinically relevant numbers, but this is done with supplementation of basal mammalian cell culture medium with growth factors. The concept of avoiding using supplements with animal substances, hPL produced from expired and pathogen inactivated platelet concentrates can be used in place of fetal bovine serum. However globally, most transfusion units are not pathogen inactivation. They aimed to assess the quality of hPL produced from expired platelet concentrates with pathogen inactivation applied after platelet lysis (compared to conventional after collection), as well as its ability to support MSC proliferation and tri-lineage differentiation.

They compared results of expanding and differentiation bone marrow MSCs using hPL derived from pathogen inactivated platelet lystes (with pathogen inactivation after lysis of expired platelets) versus using hPL produced from conventional expired pathogen inactivated human platelet concentrates (with pathogen inactivation applied soon applied soon after blood donation). THEY FOUND THAT PATHOGEN INACTIVATION AFTER LYSIS HAD LOWER CONCENTRATIONS OF SOLUBLE GROWTH FACTOR AND CYTOKINES THAN THOSE WITH CONVENTIONAL PATHOGEN INACTIVATION, AND THAT IN CELL CULTURE THE MSCS PROLIFERATED AT A REDUCED BUT MORE CONSISTENT RATE THAN THE CONVENTIONAL INACTVATION. THEY FOUND THE ABILITY TO SUPPORT TRILINEAGE DIFFERENTIATION WAS COMPARABLE BETWEEN THE LYSATES.

They interpreted their results as supportive of hPL being produced from expired and untreated platelet lysates by post lysis pathogen inactivation for global hPL production methods to increase the pool of starting material and meet future demand for animal-free supplements in human cell culturing.

The writing is clean, the methods address the aims, the results clear, the table and figures well done and interpretable, but the interpretation of the results is overreaching and the lack of comparison to the standard of fetal bovine serum disappointing.

Major issues:

1\. The very large ranges in the % differences in the growth factors between the two batches of PIPC and PIPL makes it hard to know what a representative 'baths' of these hPL really are. I believe to really make any comment on the concentrations of growth factors in this setting, and to really interpret the results, more than 2 batches must be compared. Not only are there differences between the two hPL pathogen inactivation techniques, but also between the batches of the same technique.... This is a problem for interpreting the results.

2\. It is disappointing that there is not a control with the standard fetal bovine serum. Given the literature suggests that conventional pathogen inactivated hPL is as good or better than standard fetal bovine serum, it would be important to compare this method to the conventional AND post-lysate pathogen inactivation methods. This is especially important given the concentrations of selected soluble growth factors were lower in the post-lysate pathogen inactivation group, because it is important to know if these concentrations are of equivalence to the standard bovine fetal serum (as there may be a ceiling effect in the amount of growth factor needed for proliferation and differentiation, further supporting less importance on the growth factor differences and more importance on the biologic effects)

3\. Along these lines, the study is missing a limitations section that should be added, and should include discussion of the important issues with changing from a non-human source to a human blood-product source need to be mentioned as the pathogen reduction techniques may not completely mitigate the risk of viral transmissions.

4\. The interpretation of the results should be tempered. Given there were lower concentrations of key growth factors, lower cumulative population doublings, no comparison to standard fetal bovine serum, and no study of retention of genomic stability of avoidance of tumorigenicity, it is unclear to me whether this successfully supports long term cell proliferation.

5\. Please discuss the decision to store for 3 weeks of -80 degrees. Why was this chosen? The LOS at -80 may effect results and needs to be studied going forward.

Minor issues:

1\. Please spell out the growth factors in the manuscript and in the table, they cannot be assumed to be known.

Reviewer \#2: Overall the study titled "effects of amotosalen treatment on human platelet lysate bioactivity" by Christensen et al. is sound and reveals interesting results. However, we believe the authors should address the following concerns:

1\. All the experiments were done using fresh platelets, but authors let the platelets expire. We think that experiments using the banked expired platelets should be performed to complement current findings.

2\. In every section of the results, author should provide the rationale for each of the experiments, what they did, explain the results and their inferences, as much as possible and a brief manner.

3\. In equations 1 and 3, authors should "write" multiplication symbol instead of using a "dot".

3\. In every place authors should correct CO2/CO2 (should be CO2).
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6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).
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Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]
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Below are responses to the reviewer's comments

Reviewer 1:

Comment 1: The very large ranges in the % differences in the growth factors between the two batches of PIPC and PIPL makes it hard to know what a representative 'baths' of these hPL really are. I believe to really make any comment on the concentrations of growth factors in this setting, and to really interpret the results, more than 2 batches must be compared. Not only are there differences between the two hPL pathogen inactivation techniques, but also between the batches of the same technique.... This is a problem for interpreting the results.

Response: We thank the reviewer for pointing this out. We agree with this comment and a line has been included to clarify that the individual difference of the two batches and the implication on the ability to generalize is a limitation of the study (page 12, line 213). It would indeed have been interesting to assess the concentrations of growth factors using a larger pool of batches, however for this proof-of-concept study we were only able to produce platelet concentrates from a total of 32 buffy coats. We have taken this into account for future studies.

Comment 2: It is disappointing that there is not a control with the standard fetal bovine serum. Given the literature suggests that conventional pathogen inactivated hPL is as good or better than standard fetal bovine serum, it would be important to compare this method to the conventional AND post-lysate pathogen inactivation methods. This is especially important given the concentrations of selected soluble growth factors were lower in the post-lysate pathogen inactivation group, because it is important to know if these concentrations are of equivalence to the standard bovine fetal serum (as there may be a ceiling effect in the amount of growth factor needed for proliferation and differentiation, further supporting less importance on the growth factor differences and more importance on the biologic effects).

Response: We thank the reviewer for addressing this. This is a valid point and we fully agree that a comparison to fetal bovine serum is valuable. However, for this proof-of-concept study where the central focus was to assess whether it was possible to produce platelet lysates by performing pathogen inactivation post-expiry, we believe that including fetal bovine serum would be slightly out of scope. The direct comparison between hPL and fetal bovine serum has been carried out in several papers including two by our own research group. See:

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5506010/>

<https://www.ncbi.nlm.nih.gov/pubmed/25198449>

<https://www.ncbi.nlm.nih.gov/pubmed/23874839>

Comment 3: Along these lines, the study is missing a limitations section that should be added, and should include discussion of the important issues with changing from a non-human source to a human blood-product source need to be mentioned as the pathogen reduction techniques may not completely mitigate the risk of viral transmissions.

Response: We agree and a line in the introduction has been added accordingly, clarifying that the INTERCEPT™ Blood System does not guarantee 100% pathogen reduction and is indeed bypassed by non-enveloped viruses such as hepatitis A and hepatitis E (page 4, line 54).

Comment 4: The interpretation of the results should be tempered. Given there were lower concentrations of key growth factors, lower cumulative population doublings, no comparison to standard fetal bovine serum, and no study of retention of genomic stability of avoidance of tumorigenicity, it is unclear to me whether this successfully supports long term cell proliferation.

Response: We agree with the reviewer that the results in the submitted state did not fully support the conclusion that hPL-PIPL supports long-term cell proliferation alone. We refrained from the wording "successful" and added a line in the discussion pointing out to fully elucidate the effect on long-term cell proliferation, assessment of genomic stability and tumorigenicity is important (page 13, line 225). We also added to the conclusion to clarify that hPL-PIPL is solely viewed as a results of a possible production method and may be a valuable tool moving forward, but the results do not support the notion that hPL-PIPL is better or worse than conventional hPL-PIPC. Further studies are needed to follow up on this.

Comment 5: Please discuss the decision to store for 3 weeks of -80 degrees. Why was this chosen? The LOS at -80 may effect results and needs to be studied going forward.

Response: This is a very important point. We do not have reason to believe that this had a negative impact on the quality of the end product as it has been discussed as general practice by several groups (<https://www.ncbi.nlm.nih.gov/pubmed/29071726>). For this study, we decided upon these storage conditions due to practical reasons. By the time the platelet concentrates were ready to be processed by the National Blood Bank, we were awaiting the arrival of the first donor cells. Optimally, we would have preferred the avoid storage at all, but it was not possible.

Comment 6: Please spell out the growth factors in the manuscript and in the table, they cannot be assumed to be known.

Response: We thank the reviewer for this suggestion. We have spelled out the growth factors in the manuscript.

\\f

Reviewer 2:

Comment 1: All the experiments were done using fresh platelets, but authors let the platelets expire. We think that experiments using the banked expired platelets should be performed to complement current findings.

Response: We thank the reviewer for this comment. It is important for us to stress that the platelet concentrates used in the study were all banked and allowed to expire prior to experimentation. We have previously compared fresh platelets to expired platelets (<https://www.ncbi.nlm.nih.gov/pubmed/23874839>) but this was out of the scope of this study. Rather we wanted to study the possibility of producing viable platelet lysates from expired platelet concentrates applying pathogen inactivation post-expiry. We hope this answers the reviewer's concern.

Comment 2: In every section of the results, author should provide the rationale for each of the experiments, what they did, explain the results and their inferences, as much as possible and a brief manner.

Response: We agree with this comment. However, we believe that the rationales of the experiments are well-described in the discussion section of the paper. E.g. at page 11, line 199 we argue that growth factors within the α-granules are important for MSC proliferation and differentiation and provided the basis for quantifying soluble growth factors and cytokines. At page 12, line 216 we discuss the impact of "higher" concentrations of growth factors on MSC proliferation supporting the use of the cumulative population doubling assay. Similar rationale is provided for each of the differentiation assays throughout the discussion.

Comment 3: In equations 1 and 3, authors should "write" multiplication symbol instead of using a "dot".

Response: We thank the reviewer for this suggestion. We have replaced the use of a "dot" with the multiplication symbol "x" in equation 1 and 3 at page 16, line 311 and page 20, line 401.

Comment 4: In every place authors should correct CO2/CO2 (should be CO2).

Response: We thank the reviewer for this observation. It is correct that we falsely used the term "CO2" instead of the correct form "CO2". This has been corrected at all places.
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Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

6 Feb 2020

PONE-D-19-18862R1

Effects of amotosalen treatment on human platelet lysate bioactivity

PLOS ONE

Dear Dr Sigurjonsson,

Thank you for submitting your revised manuscript to PLOS ONE. Your paper was re-reviewed by the original reviewers and one of them feels you have adequately addressed their comments, but Reviewer\#1 has residual concerns and recommends against acceptance of your work. Because this decision is split, we are providing you with a second opportunity to revise this study with the guidance of a second set of comments from the reviewers. 

We would appreciate receiving your revised manuscript by Mar 22 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Andre van Wijnen

Academic Editor

PLOS ONE

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: (No Response)

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: No

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Christensen and colleagues have submitted a revision of their reported results of an ex-vivo study of bone-marrow derived MSCs expansion and differentiation with human platelet lysates (hPL) with two different pathogen inactivation processes. Specifically, this study addresses the issue that clinical application of MSCs usually require an in vitro expansion step for clinically relevant numbers, but this is done with supplementation of basal mammalian cell culture medium with growth factors. Addressing the concept of avoiding using supplements with animal substances, hPL produced from expired and pathogen inactivated platelet concentrates can be used in place of fetal bovine serum. However, globally most transfusion units are not pathogen inactivated, so they aimed to assess the quality of hPL produced from expired platelet concentrates with pathogen inactivation applied AFTER platelet lysis (compared to conventional after collection), as well as its ability to support MSC proliferation and tri-lineage differentiation.

They compared results of expanding and differentiation of bone marrow MSCs using hPL derived from pathogen inactivated platelet lystes (with pathogen inactivation after lysis of expired platelets) versus using hPL derived from conventional expired pathogen inactivated human platelet concentrates (with pathogen inactivation applied soon applied soon after blood donation). THEY FOUND THAT PATHOGEN INACTIVATION AFTER LYSIS HAD LOWER CONCENTRATIONS OF SOLUBLE GROWTH FACTOR AND CYTOKINES THAN THOSE WITH CONVENTIONAL PATHOGEN INACTIVATION, AND THAT IN CELL CULTURE THE MSCS PROLIFERATED AT A REDUCED BUT MORE CONSISTENT RATE THAN THE CONVENTIONAL INACTVATION. THEY FOUND THE ABILITY TO SUPPORT TRILINEAGE DIFFERENTIATION WAS COMPARABLE BETWEEN THE LYSATES. They interpreted their results as supportive of hPL being produced from expired and untreated platelet lysates (by post lysis pathogen inactivation) for global hPL production methods to increase the pool of starting material and meet future demand for animal-free supplements in human cell culturing.

Unfortunately, based on my prior review, very few changes have been made in the manuscript (only a few short sentences added and a couple of words changed), and their responses do not adequately address my concerns. They have now called this study a 'proof-of-concept' study in the reviewer responses, (but this is mentioned only once in their discussion). I would suggest, that if this is indeed a 'proof-of-concept' study, this be clarified throughout the ENTIRE manuscript including adding those words to the title so this is not misleading to readers. As previously mentioned, the findings are not interpretable without more than two batches due to the very large ranges in the % differences in the growth factors between the two batches of PIPC and PIPL (not only are there differences between the two hPL pathogen inactivation techniques, but also between the batches of the same technique), and the missing bovine fetal serum comparison group (given the citations of direct comparisons performed between hPL and bovine fetal serum by this author group, there should be no reason why this cannot be performed for this study). The couple short sentences added to the manuscript without a focus on a full limitations section (as previously suggested), will not suffice given the significant limitations in current form. Given the many limitations, these should be addressed together in a true limitations section and furthermore need to include the issue raised of storage for 3 weeks at -80 especially given it was decided based on practical reasons.

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Author response to Decision Letter 1

24 Feb 2020

Below are responses to the reviewer's comments on the revised manuscript

Reviewer 1:

Comment 1: Unfortunately, based on my prior review, very few changes have been made in the manuscript (only a few short sentences added and a couple of words changed), and their responses do not adequately address my concerns

Response: Based on this and Reviewer 1's further comments on the revised manuscript, we have further expanded upon the concerns raised. Further details on specific issues are described below.

Comment 2: They have now called this study a 'proof-of-concept' study in the reviewer responses, (but this is mentioned only once in their discussion). I would suggest, that if this is indeed a 'proof-of-concept' study, this be clarified throughout the ENTIRE manuscript including adding those words to the title so this is not misleading to readers

Response: Thank you for pointing out that we needed to clarify that this is a "proof-of-concept" study throughout. As suggested, we have reworked the title and it now specifically references that this is a proof-of-concept work (page 1). We have also made sure to make this clear in the abstract (page 2, line 27), in the introduction (page 4, line 95), in multiple places in the discussion section (page 12, line 205; page 12, line 210; page 13 line 232; page 14, line 271), and in the conclusion (page 15, line 285).

Comment 3: . As previously mentioned, the findings are not interpretable without more than two batches due to the very large ranges in the % differences in the growth factors between the two batches of PIPC and PIPL (not only are there differences between the two hPL pathogen inactivation techniques, but also between the batches of the same technique), and the missing bovine fetal serum comparison group (given the citations of direct comparisons performed between hPL and bovine fetal serum by this author group, there should be no reason why this cannot be performed for this study)..

Response: This large differences between the two batches does indeed make it difficult to generalize the results of this study to hPL in general. We believe that, as this was a proof-of-concept study (unfortunately we did not make this clear in the original submission), that our results provide enough evidence to suggest that the application of pathogen inactivation after platelet lysis is worth further study. This has now been more explicitly stated in the manuscript (page 14, lines 274-282), and we have also clarified the limitations resulting from the small number of replicates (pages 12-13, lines 232-234; page 14, lines 271-274)

With regard to a comparison with FBS, we have added to the discussion a note that it was not included in this work because previous studies have shown hPL to be comparable to FBS as a cell culture supplement (page 12, lines 209-211). We have also noted that future work should include an FBS control (page 14, lines 279-280). Unfortunately, none of the studies references specifically looked at growth factor and cytokine levels in the FBS supplements used, so we cannot provide a comparison within our manuscript to previous results. We don't believe that it is warranted to analyze the levels of these factors in FBS at this point, considering the study is already complete, but, again, we have noted that this should be included in future work.

Comment 4: ). The couple short sentences added to the manuscript without a focus on a full limitations section (as previously suggested), will not suffice given the significant limitations in current form. Given the many limitations, these should be addressed together in a true limitations section.

Response: In order to address this concern, in addition to the sentences previously added into the manuscript after the initial review, we have added a paragraph at the end of the discussion section which discusses how the limitations inherent in this proof-of-concept work should be addressed in future work. Please note that the main limitations are explicitly stated within this discussion. (page 14, lines 274-282)

Comment 5: \[The limitations\] need to include the issue raised of storage for 3 weeks at -80 especially given it was decided based on practical reasons. (comment base on the initial submission: Please discuss the decision to store for 3 weeks of -80 degrees. Why was this chosen? The LOS at -80 may effect results and needs to be studied going forward.)

Response: Again, thank you for raising this important point. As we initially stated, we do not have reason to believe that this had a negative impact on the quality of the end product as it has been discussed as general practice by several groups (<https://www.ncbi.nlm.nih.gov/pubmed/29071726>). For this study, we decided upon these storage conditions due to practical reasons: by the time the platelet concentrates were ready to be processed by the National Blood Bank, we were awaiting the arrival of the first donor cells. Optimally, we would have preferred to avoid storage at all, but it was not possible.

We would also like to point out that the production of platelet lysates does involve temperature cycling from -80°C to 37°C three times, as stated in the Materials and methods section (lines 321-322). Therefore, it is not unreasonable to store the cells at -80°C, given that this temperature is used for lysis. In addition, it must be noted that even in the absence of any storage period, the cells would have been exposed to -80°C during the process of lysis, and therefore we do not have any reason to believe that the relatively brief storage period used would have had any detrimental effect on the platelets.

Finally, it is worth noting that both treatments were exposed to the -80°C storage conditions.
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25 Mar 2020

Effects of amotosalen treatment on human platelet lysate bioactivity: a proof-of-concept study

PONE-D-19-18862R2

Dear Dr. Sigurjonsson,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Andre van Wijnen

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Christensen and colleagues have submitted a revision of their reported results of an ex-vivo study of bone-marrow derived MSCs expansion and differentiation with human platelet lysates (hPL) with two different pathogen inactivation processes.

On their last revision, very few of my comments had been addressed. I appreciate that they have addressed that and have reframed the study throughout as a proof of concept study. By reframing, the issue of not being able to generalize these results beyond the two batches, and the missing bovine fetal serum comparison group are much improved. The expanded limitations section is much appreciated.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

10.1371/journal.pone.0220163.r006
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PONE-D-19-18862R2

Effects of amotosalen treatment on human platelet lysate bioactivity: a proof-of-concept study

Dear Dr. Sigurjonsson:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Andre van Wijnen

Academic Editor

PLOS ONE
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